This is a routine board expansion with experienced oncology executives. No financial guidance or operational changes were disclosed. Monitor for any strategic shifts or pipeline updates that may follow the new directors' input.
MGNX drugs
MGNX drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5- T+0 · Nov 4 $2.31entry
- T+1 · 12d ago −3.90%α +0.51% · $2.22
- T+5 · 6d ago +0.43%α +1.35% · $2.32
- T+8 · todayOpen
- T+20 · in 16d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
MacroGenics appointed two new independent directors, Emil Kuriakose and Michael Vasconcelles, to its Board, expanding the board from ten to eleven members. Both directors have extensive oncology drug development experience and were appointed to the Science and Technology Committee. This is a routine governance enhancement with no material financial impact.
Key Facts
- Board size increased from 10 to 11 members on October 30, 2026
- Michael Vasconcelles appointed as Class II director until 2027 annual meeting
- Emil Kuriakose appointed as Class III director until 2028 annual meeting
- Both directors deemed independent under Nasdaq and Exchange Act standards
- Both appointed to the Science and Technology Committee
- Each receives standard director compensation: annual retainer, option for 44,000 shares, and RSU for 7,500 shares
- Neither director was selected pursuant to any arrangement with any person
Financial Impact
Standard director compensation; initial equity grants of 44,000 options and 7,500 RSUs per director, valued at market price on grant date
Risk Factors
- No material risks identified from this filing
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001125345-26-000069 |
| Document: pressreleasekuriakoseandva.htm | 0001125345-26-000069 |
| Document: 0001125345-26-000069-index-headers.html | 0001125345-26-000069 |
| Document: 0001125345-26-000069-index.html | 0001125345-26-000069 |
| Document: 0001125345-26-000069.txt | 0001125345-26-000069 |
Track record
21 reports on MGNX
4 of 6 bullish or bearish reports moved the stock their way by T+60. Best: +130.41% at T+60 after the Feb 28, 2026 report. 8 of 9 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $2.22 Now $2.17 −2.25% settles Feb 12
- Nov 13, 20263d ago 8-K Neutral 4/10 Entry $2.31 Now $2.17 −6.06% settles Feb 12
- Nov 12, 20264d ago Press Release Bearish 5/10 Entry $2.20 Now $2.17 +1.36% settles Feb 11
- Nov 3, 202613d ago 3 Neutral 1/10 Entry $2.31 Now $2.17 −6.06% settles Feb 2
- Nov 3, 202613d ago 3 Neutral 1/10 Entry $2.31 Now $2.17 −6.06% settles Feb 2
- Nov 3, 202613d ago 8-K Neutral 2/10 Viewing Entry $2.31 Now $2.17 −6.06% settles Feb 2
- Oct 26, 202621d ago Press Release Bullish 6/10 Entry $2.19 Now $2.17 −0.91% settles Jan 22
- Oct 23, 202624d ago 8-K Bullish 7/10 Entry $2.19 Now $2.17 −0.91% settles Jan 22
- Oct 22, 202625d ago 144 Neutral 2/10 Entry $2.25 Now $2.17 −3.56% settles Jan 21
- Oct 15, 20264w ago Press Release Neutral 3/10 Entry $3.25 Now $2.17 −33.23% settles Jan 13
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers